4.2 Review

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia

Journal

VOX SANGUINIS
Volume 108, Issue 1, Pages 1-10

Publisher

WILEY
DOI: 10.1111/vox.12201

Keywords

haemoglobin E; thalassaemia; haemoglobin H disease; iron chelation; non-transfusion-dependent thalassaemia; red cell transfusion; -thalassaemia intermedia

Categories

Funding

  1. Novartis Pharmaceuticals

Ask authors/readers for more resources

Non-transfusion-dependent thalassaemia (NTDT) refers to all thalassaemia disease phenotypes that do not require regular blood transfusions for survival. Thalassaemia disorders were traditionally concentrated along the tropical belt stretching from sub-Saharan Africa through the Mediterranean region and the Middle East to South and South-East Asia, but global migration has led to increased incidence in North America and Northern Europe. Transfusionists may be familiar with -thalassaemia major because of the lifelong transfusions needed by these patients. Although patients with NTDT do not require regular transfusions for survival, they may require transfusions in some instances such as pregnancy, infection or growth failure. The complications associated with NTDT can be severe if not properly managed, and many are directly related to chronic anaemia. Awareness of NTDT is important, and this review will outline the factors that should be taken into consideration when deciding whether to initiate and properly plan for transfusion therapy in these patients in terms of transfusion interval and duration of treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available